MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- AUROBINDO PHARMA
AUROBINDO PHARMA Share Price (AUBD)
Here is the latest stock price and chart of Aurobindo Pharma. For more details, see the Aurobindo Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Jul 23, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)561.75 | Open (Rs) 571.00 | High (Rs) 574.85 | Low (Rs) 558.45 |
| % Change-1.50 | Volume 69,284 | Value (Rs) 39,188,710 | 52-Week H/L 838.00 / 546.00 |
| Live NSE Quotes | Jul 23, 2019 (Close) | ||
|---|---|---|---|
| Price (Rs)561.75 | Open (Rs) 570.15 | High (Rs) 574.75 | Low (Rs) 558.25 |
| % Change-1.47 | Volume 1,929,978 | Value (Rs) 1,092,297,362 | 52-Week H/L 838.00 / 546.05 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 40.36 | P/E Ratio (x) 13.92 | Market Cap (Rs m) 328,718.69 | P/BV (x) 2.81 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
Free Report: Multibagger Stocks of 2019 - Know How to Pick Best Stocks
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
AUROBINDO PHARMA Share Price Today:
AUROBINDO PHARMA last traded price was down 1.5% to Rs 561.8 on the BSE. On the NSE, AUROBINDO PHARMA last traded price was down 1.5% to Rs 561.8. The total volume of shares traded was 2.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was down by 0.3%. And the benchmark S&P BSE SENSEX was at 37,982.7 (down 0.1%).
Over the last 30 days, the AUROBINDO PHARMA share price is down 4.2%. And over the last one year, AUROBINDO PHARMA share price is down 4.6%.
|
| |
Today's Market
Sensex below 38,000-Mark, HUL, L&T Q1FY20 Results, and Top Stocks in Action Today(Pre-Open)
On Tuesday, Indian share markets extended their decline for the 4th day as markets witnessed selling pressure during closing hours.
Related Views On News
AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)
May 30, 2019 | Updated on May 30, 2019For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
The Electric Vehicle Disruption is Great News for this Smallcap Stock (Profit Hunter)
Jul 15, 2019While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.
7 Stocks to Profit From an Irreversible Trend (The 5 Minute Wrapup)
Jul 18, 2019Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.
Driverless Cars are Here. And This Tiny Company is in the Lead... (The 5 Minute Wrapup)
Jul 17, 2019This future-ready company thrives on the pace of technological change.
Here's Why This Smallcap Will Beat the Big Autos in the EV Race (Profit Hunter)
Jul 16, 2019As the conventional auto sector faces existential crisis, my latest smallcap recommendation is all set to ride the electric vehicle disruption and rise in new age vehicles.
MoreTRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - DIVIS LABORATORIES COMPARISON
COMPARE AUROBINDO PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.